Navigation Links
NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting
Date:5/7/2008

nution of morphine-induced miosis, a CNS effect, was observed at single oral doses of NKTR-118 of 125 mg or less. In addition, NKTR-118 at single doses up to 1,000 mg was well-tolerated. The drug was rapidly absorbed with dose-proportional pharmacokinetics over the 8-1,000 mg dose range.

Data Presentations for NKTR-118

The poster presentation made this week at the APS Meeting, as well previous data presentations for NKTR-118, can be found on Nektar's website at http://www.nektar.com/wt/page/nktr118_media

APS Poster #210: "Results from a Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study Evaluating the Safety, Tolerability and Pharmacokinetics of Oral Doses of NKTR-118 (PEG-Naloxol)"

About NKTR-118

Oral NKTR-118 is currently in a Phase 2 study to evaluate the efficacy, safety and tolerability of once-daily doses in patients with opioid-induced constipation (OIC). The investigational drug combines Nektar's advanced small molecule PEGylation technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. In a Phase 1 clinical study, Nektar's PEGylation technology has been shown to reduce penetration of oral NKTR-118 across the blood-brain barrier, an important potential advance for this and possibly many other small molecule therapies.

The antagonist NKTR-118 targets mu-opioid receptors within the enteric nervous system, which mediate OBD, a symptom complex resulting from opioid use that encompasses constipation, bloating, abdominal cramping, and gastroesophageal reflux. Constipation is the hallmark of this syndrome, and is generally its most prominent component. Many studies indicate that a high percentage of patients receiving opioids are likely to experience significant constipation and other symptoms of OBD. According to IMS Health, about 230 million prescriptions were written for opioids in 2007 in the Un
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
2. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
3. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
4. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
5. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
6. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
7. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
8. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
9. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
10. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
11. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/13/2008)... Potential New Approach for the Treatment of Infla...lestone Triggers $10 Million Payment from Partner ...RNewswire/ -- ChemoCentryx, Inc., today,announced ...54, an,orally-available, novel small molecule comp...okine receptor which is associated with inflammato...
(Date:5/12/2008)...NCISCO, Calif., May 12 /- N...nnounces that it presented a,poster in collaborati...ment,of a patient reported outcomes questionnaire ...QoL) aspects of chronic diarrhea in persons living...or Pharmacoeconomics and,Outcomes Research (ISPOR)...
(Date:5/12/2008)...opens way for high-power permanent version of the ...udy, BOSTON, May 12 /- Innovative pr...nd the daily lives of patients with,hemianopia, a ...h eyes. The,peripheral prism glasses, which were i...epens Eye Research Institute, were evaluated in th...
(Date:5/12/2008)...adjust their function like a radio dial, not an on...utoimmune disease may develop,late in life, MEM...t. Jude Children,s,Research Hospital study shows t...do not use simple on/off switches to govern the ce...and function. Rather, they,possess sophisticated m...
Breaking Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 2ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 3ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 4ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 5Napo Presents at ISPOR Meeting in Toronto 2Prism Glasses Expand the View for Patients with Hemianopia 2Prism Glasses Expand the View for Patients with Hemianopia 3St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 2St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 3St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 4European lead in reading past climates from ice cores 759 1European lead in reading past climates from ice cores 759 2European lead in reading past climates from ice cores 759 3ReBuilder Medical Technologies Inc Announces Agreement with Internet Marketer Helio Health 3B Anticipates 12 25 Additional Profit 3466 1ReBuilder Medical Technologies Inc Announces Agreement with Internet Marketer Helio Health 3B Anticipates 12 25 Additional Profit 3466 2ReBuilder Medical Technologies Inc Announces Agreement with Internet Marketer Helio Health 3B Anticipates 12 25 Additional Profit 3466 3CVS pharmacy to Remove OTC Infant Cough 26 Cold Products from Its Stores as Part of CHPAs Voluntary Withdrawal 3463 1CVS pharmacy to Remove OTC Infant Cough 26 Cold Products from Its Stores as Part of CHPAs Voluntary Withdrawal 3463 2Yoplait 28R 29 Challenges One Million Americans to Pledge to Their Breast Health 3460 1Yoplait 28R 29 Challenges One Million Americans to Pledge to Their Breast Health 3460 2Yoplait 28R 29 Challenges One Million Americans to Pledge to Their Breast Health 3460 3
...herapeutics,Inc., a specialty pharmaceutical comp...ry and infectious diseases, today announced,the co...scana,– a topical formulation designed to tr...rimary end point and demonstrated statistical,sign...atient,population. Typically, a probability value...
...s and upcoming,milestones on its insulin program -...SemBioSys,Genetics Inc. , a biotechnology company ... metabolic and cardiovascular disease,today annou...lopment of plant-derived recombinant human insulin...cientific Sessions of the,American Diabetes Associ...
Other Medicine Technology:MediQuest Concludes Confirmatory Phase III Study of Raynaud’s,Therapy 2SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 2SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 3SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 4
(Date:5/13/2008)... HARBIN, China, May 13 /Xinhua-PRNewswire-FirstCa...oard: CSKI), a manufacturer, marketer and,distribu...oducts in China,today announced that it will cond... May 15, 2008 to discuss its first quarter 2008 fi...man, CEO and Director of China Sky One,Medical, In...
(Date:5/13/2008)...ildbearing had no such benefit if baby was bottle-...13 (HealthDay News) -- Women who breast feed for m...arthritis (RA) by half, according to a new Swedish...g children but not breast-feeding offered women no...contraceptives also failed to reduce the risk of R...
(Date:5/13/2008)...NEW YORK (May 13, 2008) -- Promising results from ...ell Medical Center physician-scientists show that ... the progression of Batten disease, or Late Infant..., genetic, degenerative neurological disorder that... to 12. , The clinical trial found that the pro...
(Date:5/13/2008)... SALT LAKE CITY, May 13 /PRNewswire/ -- Paramed S...ent of their marine-grade Mobility Offers,Versatil...chair to oil and,gas platform operators in the Gul...platforms will enable the safe and timely evacuati...atform., Paramed developed the dual-track MOV in ...
Breaking Medicine News(10 mins):Health News:China Sky One Medical, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Breast-feeding Might Shield Women From Rheumatoid Arthritis 2Health News:NYP/Weill Cornell gene therapy clinical trial yields promising results for Batten disease 2
... tissue abnormalities, or lesions, that typically ...nfected with multiple genotypes// of the human pap...ing to a study published in the July issue of Canc...ion. Although doctors have known that the cervica...
...ter is among 10 institutions selected to oversee i...ving interventions for critical trauma// and sudde...th has joined with other U.S. and Canadian agencie...on Outcomes Consortium (ROC) and establish federal...
...ttle super bugs, including MRSA, has found its way...d the news as Tygacil, is one of the few new antib...rs. Micro organisms have undergone mutations that...sistance to the existing antibiotics, leading to w...
...sleep would probably help the human brain to enhan...arned facts.// It was reported that previous stud...declarative memories, like the steps of learning t... It was explained that the new experiment focuses ...
Other Medicine News:Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 2Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 3Health News:Medical Center to Test Methods of Improving Cardiac Arrest, Trauma Survival 2Health News:New Drugs To Combat Mutant Bugs 2Health News:Sleep Essential For A Strong Memory 2
...sists of a sterile Hemostatic Dressing supplied to...,Both devices work together to promote dual-action...cal hemostasis by facilitating clotting at the ski...tem provides external compression to facilitate cl...
The ALLEGRO Analyzer has been specifically designed to deliver wavefront data needed to perform safe and successful wavefront guided laser vision correction. All components such as the user interface
Absolute precision demands absolute knowledge. Access it with the Bausch & Lomb Zyoptix Diagnostic Workstation, uniting two trusted technologies: Zywave II Wavefront Aberrometer and Orbscan IIz Anter
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e
Medicine Products: